Investigation of Ocular Signs & Symptoms in Wearers Fitted With Contact Lenses Following Digital Device Use

NCT ID: NCT02394756

Last Updated: 2018-06-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 52 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-02-28
• Study Completion Date: 2015-09-30

Brief Summary

The objective of this study is to assess how various silicone hydrogel lenses perform when worn by subjects who are heavy digital device users.

Conditions

Visual Performance

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Marketed Soft Contact Lens (Test)

Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.

Group Type: EXPERIMENTAL

Marketed Soft Contact lens

Intervention Type: DEVICE

Replacement schedule every 2 weeks

AIR OPTIX® AQUA

Intervention Type: DEVICE

Replacement schedule every 4 weeks

Biofinity®

Intervention Type: DEVICE

Replacement schedule every 4 weeks

AIR OPTIX® AQUA

Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.

Group Type: ACTIVE_COMPARATOR

Marketed Soft Contact lens

Intervention Type: DEVICE

Replacement schedule every 2 weeks

AIR OPTIX® AQUA

Intervention Type: DEVICE

Replacement schedule every 4 weeks

Biofinity®

Intervention Type: DEVICE

Replacement schedule every 4 weeks

Biofinity®

Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.

Group Type: ACTIVE_COMPARATOR

Marketed Soft Contact lens

Intervention Type: DEVICE

Replacement schedule every 2 weeks

AIR OPTIX® AQUA

Intervention Type: DEVICE

Replacement schedule every 4 weeks

Biofinity®

Intervention Type: DEVICE

Replacement schedule every 4 weeks

Interventions

Marketed Soft Contact lens

Replacement schedule every 2 weeks

Intervention Type: DEVICE

AIR OPTIX® AQUA

Replacement schedule every 4 weeks

Intervention Type: DEVICE

Biofinity®

Replacement schedule every 4 weeks

Intervention Type: DEVICE

Other Intervention Names

senofilcon A; lotrafilcon B; comfilcon A

Eligibility Criteria

Inclusion Criteria

1. The subject must read, understand and sign the statement of Informed Consent and receive a fully executed copy of the form.

2. The subject must be between 18 and 40 years of age.

3. The subject's vertex corrected spherical equivalent distance refraction must be in the range of -0.50D to -8.00D in each eye.

4. The subject's refractive cylinder must be no more than -1.25 D cylindrical correction in each eye after vertexing to the corneal plane.

5. The subject must have best corrected visual acuity of 0.20 or better in each eye.

6. The subject must be a current wearer of daily, spherical, soft contact lenses (no bifocal or multifocal contact lenses, no extended wear or monovision) for at least 5 days/ week and at least 8 hours/day during the month prior to enrollment.

7. The subject must be using digital devices (any combination of computers, tablets, smartphones, etc.) for at least 8 hours over the course of a typical day.

8. The subject should own a wearable pair of spectacles and wear them the day of the baseline visit.

9. The subject must have normal eyes with no evidence of abnormality or disease that in the opinion of the investigator would contraindicate contact lens wear.

10. The subject must meet normal eligibility conditions of binocular vision tests.

11. The subject may not have any double vision at near with their habitual contact lens correction.

Exclusion Criteria

1. Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).

2. Any ocular or systemic allergies or diseases that may interfere with contact lens wear (at the investigator's discretion).

3. Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear (at the investigator's discretion).

4. Use of any medication that causes side effects similar to side effects experienced when using digital devices, such as subjects reporting headaches associated with birth control pills (at the investigator's discretion).

5. Any infectious disease (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease.

6. Any active ocular infection.

7. Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion by keratometry.

8. Any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, etc.).

9. Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear.

10. Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which might interfere with contact lens wear.

11. Any known hypersensitivity or allergic reaction to the study products.

12. Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.

13. History of binocular abnormality or strabismus.

14. Employee of investigational clinic (e.g. Investigator, Coordinator, Technician).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Johnson & Johnson Vision Care, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Waterloo, Ontario, Canada

Countries

Canada

Other Identifiers

CR-5615

Identifier Type: -

Identifier Source: org_study_id